ArticleJournal of translational autoimmunity2026
Longitudinal evolution of rheumatoid factor-expressing lymphoma precursors in a patient with Sjögren's disease.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with Sjögren's disease (SjD) have an increased risk of developing B cell lymphomas, which may express rheumatoid factors (RhF). However, it remains unclear whether RhF-secreting cells undergo malignant transformation. To address this question, we longitudinally tracked the evolution of a RhF clone in a rare SjD case before and after lymphoma diagnosis. Methods: Peripheral blood B cells, serum and malignant lymph node biopsy were collected from a 68-year-old male with SjD who developed diffuse large B cell lymphoma (DLBCL). Clonal RhF sequences were identified in serum by mass spectrometry and in B cells by mRNA sequencing. Recombinant IgM were generated from clonal sequences and assessed for RhF activity and cryoaggregation. Results: A monoclonal RhF was detected in serum and circulating B cells six months before DLBCL diagnosis. The same clone was expressed by the lymphoma. Clonal analysis demonstrated divergence into two branches: one with seven antibody mutations expressed by blood B cells, and a second with twelve antibody mutations in the serum RhF and lymphoma. Recombinant IgM representing the blood and serum RhF demonstrated RhF activity, whereas the lymphoma clone acquired three additional mutations that impaired RhF binding. Conclusions: Our prospective and longitudinal analyses provide direct evidence for a RhF secreting clone evolving into a lymphoma in a SjD patient. This work expands on previous cross-sectional studies of RhF expressing lymphomas in SjD and provides a proof-of-concept case, which potentially supports early therapeutic targeting of expanded RhF clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.